Access to anti-retroviral drugs, female in Cameroon

Cameroon: Access to anti-retroviral drugs, female was 95.0% in 2024. ◆ Volatile

Latest (2024)
95.0%
Change on year
up 2.2%
World rank
19th
of 141 countries
All-time high
95.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Cameroon, 2000–2024

0204060801002000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 2 %2005: 4 %2006: 5 %2007: 8 %2008: 10 %2009: 13 %2010: 15 %2011: 18 %2012: 26 %2013: 28 %2014: 31 %2015: 36 %2016: 44 %2017: 54 %2018: 61 %2019: 67 %2020: 75 %2021: 82 %2022: 88 %2023: 93 %2024: 95 %

Source: UNAIDS estimates. Measured in %.

Analysis

Cameroon recorded 95.0% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.

The figure is up 2.2% on the previous year and up 206.5% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Cameroon peaked at 95.0% in 2024 and was at its lowest, 0.0%, in 2000.

Cameroon ranks 19th of 141 countries on this measure, in the top quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Cameroon, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Cameroon, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 2.0%
2005 4.0% +100.0%
2006 5.0% +25.0%
2007 8.0% +60.0%
2008 10.0% +25.0%
2009 13.0% +30.0%
2010 15.0% +15.4%
2011 18.0% +20.0%
2012 26.0% +44.4%
2013 28.0% +7.7%
2014 31.0% +10.7%
2015 36.0% +16.1%
2016 44.0% +22.2%
2017 54.0% +22.7%
2018 61.0% +13.0%
2019 67.0% +9.8%
2020 75.0% +11.9%
2021 82.0% +9.3%
2022 88.0% +7.3%
2023 93.0% +5.7%
2024 95.0% +2.2%

Averages by decade

DecadeAverage LowestHighest Years
2000s 4.2% 0.0% 13.0% 10
2010s 38.0% 15.0% 67.0% 10
2020s 86.6% 75.0% 95.0% 5

Countries ranked near Cameroon

  1. 19 Sierra Leone 95.0% compare
  2. 19 Tajikistan 95.0% compare
  3. 22 France 93.0% compare
  4. 22 Malawi 93.0% compare
  5. 22 Morocco 93.0% compare

See the full ranking of 160 places →

More gender data for Cameroon

All data for Cameroon →

Frequently asked questions

What is access to anti-retroviral drugs, female in Cameroon?
Access to anti-retroviral drugs, female in Cameroon was 95.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Cameroon?
The highest recorded value was 95.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Cameroon?
The lowest recorded value was 0.0% in 2000.
How does Cameroon rank for access to anti-retroviral drugs, female?
Cameroon ranks 19th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Cameroon?
Over the last ten years it is up 206.5%. The long-run trend across the full record is volatile.
Where does this Cameroon data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Cameroon. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/cameroon/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/cameroon/">Access to anti-retroviral drugs, female in Cameroon</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.